AMLX FY 2023 Earnings — Amylyx Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMLXAmylyx Pharmaceuticals, Inc.

$1B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$381M+1612.9% YoY

Gross Profit

$355M93.3% margin

Operating Income

$39M10.2% margin

Net Income

$49M12.9% margin

EPS (Diluted)

$0.70

Cash Flow

Operating Cash Flow

$12M

Free Cash Flow

$11M

Stock-Based Comp.

$37M

Balance Sheet

Total Assets

$517M

Total Liabilities

$84M

Stockholders' Equity

$433M

Cash & Equivalents

$170M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$381M	$22M	+1612.9%
Gross Profit	$355M	$19M	+1747.2%
Operating Income	$39M	-$201M	+119.3%
Net Income	$49M	-$198M	+124.8%